Breaking News

Achillion Appoints CSO

January 4, 2016

Barrish brings more than 30 years of pharmaceutical industry experience

Joel Barrish, Ph.D., has been appointed chief scientific officer and executive vice president, Achillion Pharmaceuticals. Dr. Barrish has more than 30 years of experience in the pharmaceutical industry. Most recently, he was vice president and head of Discovery Chemistry at Bristol-Myers Squibb, leading chemical research on small molecules and other modalities across all therapeutic areas and sites. Prior to that, he was responsible for teams at BMS that advanced more than 20 compounds into clinical development including SPRYCEL (dasatinib) for the treatment of chronic myelogenous leukemia, which he co-invented.

“It is with great excitement that we welcome Joel to Achillion as CSO,” said Milind Deshpande, Ph.D., president and chief executive officer of Achillion. “Joel is a highly accomplished drug hunter who has co-invented and developed multiple clinical compounds, including the highly successful marketed therapeutic Sprycel for which he received The Thomas Alva Edison Award. We look forward to him continuing his work to address the needs of patients by stewarding Achillion’s expanding portfolio of complement factor D inhibitors including ACH-4471 which is poised to enter clinical development.”
  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.